Zugänglichkeit
Animation
Zugänglichkeit

Manuscript

Bladder Cancer, Loss of Y Chromosome, and New Opportunities for Immunotherapy

January 10, 2024

The use of immune checkpoint inhibitors (ICI) in patients with bladder cancer (BC) is currently limited. Patients with BC who have experienced loss of the Y chromosome (LOY) often exhibit an aggressive cancer phenotype. In these LOY BC cases, CD8+ T cell exhaustion hampers the development of a robust anti-tumor response. However, there is a subset of patients with LOY BC who may show increased responsiveness to ICIs, suggesting a potential avenue for more effective treatment.

Published in: Advances in Therapy